Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual MeetingPRNewsWire • 09/08/22
IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/22
IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/10/22
IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/22
IGM Biosciences Announces Closing of Global Collaboration Agreement with SanofiGlobeNewsWire • 05/06/22
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/29/22
IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with SanofiGlobeNewsWire • 03/29/22
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation TargetsGlobeNewsWire • 03/29/22
IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19GlobeNewsWire • 02/09/22
Here's Why IGM Biosciences, Inc. (IGMS) is Poised for a Turnaround After Losing 50.6% in 4 WeeksZacks Investment Research • 01/10/22